It can be taken at any time of the day, with or without food
Zepbound (tirzepatide) is a prescription medication approved by the FDA for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbid condition
Ready to give semaglutide a try
Together, well help you achieve your health goals with confidence and expert care
Common side effects during the adjustment period (typically the first 24 weeks): Mild nausea usually less intense than when first starting a GLP-1 medication Changes in appetite (some patients notice less appetite suppression early on at the starting 0.25 mg dose) Mild stomach discomfort, bloating, or constipation Injection site reactions Side effects that are less likely during the switch (compared to first-time GLP-1 use), but still possible: Significant vomiting less common given prior GLP-1 exposure, but possible Hypoglycemia particularly relevant for type 2 diabetes patients on insulin or sulfonylureas
Safety Protocols and Sterility Self-administration requires a commitment to sterile technique to avoid infections or injection site reactions
